Literature DB >> 30112695

Immediate and later impacts of antimicrobial consumption on carbapenem-resistant Acinetobacter spp., Pseudomonas aeruginosa, and Klebsiella spp. in a teaching hospital in Brazil: a 10-year trend study.

Marilia P Federico1,2, Guilherme H Furtado3.   

Abstract

To evaluate trends and the immediate and late impact of antimicrobial consumption on carbapenem-resistant Acinetobacter spp. (CRAs), carbapenem-resistant Pseudomonas aeruginosa (CRPA), and carbapenem-resistant Klebsiella spp. (CRKs) over a 10-year period. An ecological study was conducted at the teaching hospital in São Paulo, Brazil, from 2007 to 2016. Consumption and resistance data were collected from the supply sector and central laboratory of the institution, respectively. Associations between consumption and resistance were analyzed in the same year, 1 year later, and 2 years later by linear regression of mixed effects. A total of 22,041 isolates were analyzed. Among these, 9988 corresponded to the gram-negatives in this study [3682 (36.9%) were Klebsiella spp., 3169 (31.7%) were P. aeruginosa, and 3137 (31.4%) were Acinetobacter spp.]. An increasing trend of consumption was observed, except for fourth-generation cephalosporins. Carbapenems were the most used antimicrobial class; CRKs presented a substantial increase over this period (from 1.4 to 67.0%; p = 0.001). Increased consumption of third-generation cephalosporins reduced CRAs [- 2.43%, 95% confidence interval (CI), - 3.30 to - 1.57; p < 0.001] and increased CRPA [26.67%, 95% CI, 2.99 to 50.35; p = 0.034] in the same year. Increased consumption of β-lactam/β-lactamase inhibitors increased CRKs with a 1-year delay [5.13%, 95% CI, 2.40 to 7.86; p = 0.001]. Our study demonstrated high antimicrobial consumption and growing carbapenem-resistance rates among gram-negative bacteria, especially Klebsiella spp., and the immediate and later effects of consumption of multiple antimicrobials on carbapenem resistance.

Entities:  

Keywords:  Acinetobacter spp.; Antimicrobial consumption; Antimicrobial resistance; Carbapenem resistance; Klebsiella spp.; Pseudomonas aeruginosa

Mesh:

Substances:

Year:  2018        PMID: 30112695     DOI: 10.1007/s10096-018-3352-1

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  1 in total

Review 1.  Carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter baumannii in the nosocomial setting in Latin America.

Authors:  Jaime A Labarca; Mauro José Costa Salles; Carlos Seas; Manuel Guzmán-Blanco
Journal:  Crit Rev Microbiol       Date:  2014-08-27       Impact factor: 7.624

  1 in total
  4 in total

1.  Changing Epidemiology and Decreased Mortality Associated With Carbapenem-resistant Gram-negative Bacteria, 2000-2017.

Authors:  Ahmed Babiker; Lloyd G Clarke; Melissa Saul; Julie A Gealey; Cornelius J Clancy; M Hong Nguyen; Ryan K Shields
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

2.  Association between Antimicrobial Consumption and the Prevalence of Nosocomial Carbapenem-Resistant Escherichia coli and Klebsiella pneumoniae in a Tertiary Hospital in Northern Taiwan.

Authors:  Mei-Chun Lee; Hsun Chang; Fang-Ju Sun; Alice Ying-Jung Wu; Chien-Hung Lu; Chun-Ming Lee
Journal:  Am J Trop Med Hyg       Date:  2022-06-13       Impact factor: 3.707

3.  Carbapenem-resistant Pseudomonas aeruginosa and carbapenem use in Japan: an ecological study.

Authors:  Fumitaka Terahara; Hiroshi Nishiura
Journal:  J Int Med Res       Date:  2019-08-01       Impact factor: 1.671

4.  Resistance Trends of Klebsiella pneumoniae Causing Urinary Tract Infections in Chongqing, 2011-2019.

Authors:  Shifeng Huang; Siqiang Niu; Yanhui Ding; Huijuan Wang; Shuli Pu
Journal:  Infect Drug Resist       Date:  2021-02-09       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.